All In Biotech

Drug Trial Radar · NCT07154745

A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently

A Single Arm Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Control of Intravascular Hemolysis on Currently Available C5 Inhibitor Therapy

Last checked: Nov 20, 2026Latest source record: Aug 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

35

Planned (sponsor's estimate)

Start

Jun 11, 2026

Primary completion

Jan 18, 2030

Study completion Dec 4, 2031

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Sep 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching a treatment combination with two experimental drugs called pozelimab and cemdisiran referred to as "study drugs". Researchers are looking for a better way to treat Paroxysmal Nocturnal Hemoglobinuria (PNH). The aim of the study is to see how well the pozelimab and cemdisiran combination works to lower hemolysis in participants whose PNH has been not well controlled even after taking other complement component 5 (C5) inhibitors, eculizumab/eculizumab biosimilar, ravulizumab or crovalimab. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs? * How much of the study drugs are in the blood at different times? * Whether the body makes antibodies against the study drug (which could make the study drugs not work as well or could lead to side effects)

Conditions

  • Paroxysmal Nocturnal Hemoglobinuria

Interventions

  • PozelimabDrug

    Administered per the protocol

  • CemdisiranDrug

    Administered per the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change in Lactate Dehydrogenase (LDH) during TPTime frame: From baseline to week 28

Locations

20 sites in 7 countries. Site status is shown where the registry gives one.

  • Hospital Santa Marcelina

    São Paulo, Brazil · Recruiting

  • Hospital das Clinicas da FMRP USP

    Ribeirão Preto, São Paulo, Brazil · Recruiting

  • Faculdade de Medicina do ABC

    Santo André, São Paulo, Brazil · Recruiting

  • CISSS-CA

    Lévis, Quebec, Canada · Recruiting

  • SC Hematology, AOU Città della Salute e della Scienza di Torino

    Torino, Italy · Recruiting

  • Universita Cattolica del Sacro Cuore - Policlinico Universitario A. Gemelli

    Rome, Lazio, Italy · Recruiting

  • AOU Careggi

    Florence, Tuscany, Italy · Recruiting

  • In-Vivo Sp. z o.o.

    Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland · Recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Recruiting

  • Severance Hospital

    Seoul, South Korea · Recruiting

  • Seoul St. Mary's Hospital - The Catholic University of Korea

    Seoul, South Korea · Recruiting

  • Ewha Womans University Mokdong Hospital

    Seoul, South Korea · Recruiting

  • Samsung Medical Center

    Seoul, South Korea · Recruiting

  • Institut Catala d'Oncologia

    Barcelona, Spain · Recruiting

  • Hospital San Pedro de Alcantara

    Cáceres, Spain · Recruiting

  • Hospital General JM Morales Meseguer

    Murcia, Spain · Recruiting

  • Hospital Universitario de Salamanca

    Salamanca, Spain · Recruiting

  • Hospital Universitario Basurto

    Bilbao, Vizcaya, Spain · Recruiting

  • Istanbul University Istanbul Faculty of Medicine

    Istanbul, Turkey (Türkiye) · Recruiting

  • Ege University

    Izmir, Turkey (Türkiye) · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.